People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2018 |
| Octave Bioscience Inc | — | Biotech | Series B | $105.8M | $169.5M | 2020 |
| Rezo Therapeutics, Inc. | — | Biotechnology | Series C | $46.3M | $868.3M | 2022 |
| Encentrio Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $400K | $4.1M | 2023 |
George Scangos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside George Scangos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Brook Byers | 1 | 13 |
| Tiba Aynechi | 1 | 9 |
| Vineeta Agarwala | 1 | 8 |
| Simeon George | 1 | 8 |
| Robert More | 1 | 7 |
| Thomas Hawes | 1 | 6 |
| Andrea Jackson | 1 | 6 |
| Vicki Sato | 1 | 6 |
| Mark Weeks | 1 | 4 |
| Saira Ramasastry | 1 | 4 |
| William Hagstrom | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Thomas Daniel | 1 | 4 |
| Dipchand Nishar | 1 | 3 |
| Robert Perez | 1 | 3 |
| Sung Lee | 1 | 2 |
| Norbert Bischofberger | 1 | 2 |
| Lucy Coassin | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.